Could Ra Pharmaceuticals, Inc. (RARX) See a Reversal After This Very Strong Session?

April 17, 2018 - By Peter Erickson

The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) is a huge mover today! The stock increased 4.79% or $0.28 during the last trading session, reaching $6.13. About 124,098 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has declined 74.40% since April 17, 2017 and is downtrending. It has underperformed by 85.95% the S&P500.
The move comes after 7 months positive chart setup for the $197.92 million company. It was reported on Apr, 17 by We have $6.31 PT which if reached, will make NASDAQ:RARX worth $5.94M more.

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Coverage

Among 2 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ra Pharmaceuticals had 2 analyst reports since October 24, 2017 according to SRatingsIntel. The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has “Outperform” rating given on Friday, November 10 by Credit Suisse. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, October 24 report.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $197.92 million. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.